Protection against cyclophosphamide‐induced alopecia by sulfhydryl‐containing agents in the newborn rat animal model

Background Alopecia is a common side‐effect of cancer chemotherapy. Although this complication has been known for many decades, little progress has been made in its prevention or treatment. Previously, we made the following observations: (a) treatment of 8‐day‐old rats with 1‐0‐n‐arabinofuranosylcytosine (ara‐C), doxorubicin, and cyclophosphamide (CYC) produced either total body alopecia (ara‐C and CYC) or alopecia confined to the head and proximal part of the neck (doxorubicin); (b) Imuvert, a biological response modifier, and interleukin‐1 protected against alopecia‐induced by ara‐C; and (c) neither Imuvert or interleukin‐1 protected against CYC‐induced alopecia.

[1]  A. Hussein.  Chemotherapy-Induced Alopecia: New Developments , 1993, Southern medical journal.

[2]  B. Carnes,et al.  Protection against late effects of radiation by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. , 1991, Cancer research.

[3]  A. Hussein.  Interleukin 1 protects against 1-beta-D-arabinofuranosylcytosine-induced alopecia in the newborn rat animal model. , 1991, Cancer research.

[4]  J. Jimenez,et al.  Protection from chemotherapy-induced alopecia in a rat model. , 1990, Science.

[5]  G. Andriole,et al.  The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Scheulen,et al.  Prevention of adriamycin cardiotoxicity by niacin, isocitrate or N-acetyl-cysteine in mice. A morphological study. , 1986, Pathology, research and practice.

[7]  J. Glick,et al.  WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Chaviano,et al.  Experimental cytoxan cystitis and prevention by acetylcysteine. , 1985, The Journal of urology.

[9]  K. O. Baxley,et al.  Alopecia: Effect on cancer patients' body image , 1984, Cancer nursing.

[10]  J. Kim,et al.  Topical use of N-acetylcysteine for reduction of skin reaction to radiation therapy. , 1983, Seminars in oncology.

[11]  J. Brown,et al.  The use of drugs which deplete intracellular glutathione in hypoxic cell radiosensitization. , 1982, International journal of radiation oncology, biology, physics.

[12]  T. Mcelwain,et al.  The effect of s-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR2721) on the toxicity of melphalan on normal and tumor tissue in mice , 1982 .

[13]  Phillips Tl.  Sensitizers and protectors in clinical oncology. , 1981 .

[14]  J. Critchley,et al.  Intravenous N-acetylcysteine: still the treatment of choice for paracetamol poisoning. , 1979, British medical journal.

[15]  J. Weikel,et al.  Acetylcysteine in the prevention of cyclophosphamide-induced cystitis in rats. , 1973, Journal of the National Cancer Institute.

[16]  A. Primack.  Amelioration of cyclophosphamide-induced cystitis. , 1971, Journal of the National Cancer Institute.

[17]  J. Hebebrand,et al.  Influence of sulfur-containing compounds on the acute toxicity of cyclophosphamide in male Sprague-Dawley rats. , 1984, Arzneimittel-Forschung.

[18]  T. Phillips.  Sensitizers and protectors in clinical oncology. , 1981, Seminars in oncology.